Clinical Trials Logo

Septic Shock clinical trials

View clinical trials related to Septic Shock.

Filter by:

NCT ID: NCT02972827 Active, not recruiting - Septic Shock Clinical Trials

Monitoring Devices in Prediction of Fluid Responsiveness in Severe Sepsis and Septic Shock

Start date: May 2015
Phase: N/A
Study type: Interventional

Comparison of noninvasive cardiac output monitor (NICOM, Cheetah Medical) with Edwards FloTrac minimally-invasive cardiac output monitor in predicting fluid responsiveness in sepsis and septic shock.

NCT ID: NCT02963454 Recruiting - Septic Shock Clinical Trials

Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock

Start date: January 2011
Phase: N/A
Study type: Interventional

To investigate changes in the concentration of glucose, lactate, pyruvate and glycerol in the extracellular fluid of the skeletal muscle following levosimendan administration in patients with septic shock.

NCT ID: NCT02962700 Recruiting - Septic Shock Clinical Trials

Effects of Continuous Haemofiltration vs Intermittent Haemodialysis on Microcirculatory Parameters in Septic Shock

Start date: January 2016
Phase: N/A
Study type: Interventional

The aim of the study was to investigate whether CVVH, in comparison to intermittent haemodialysis (IHD), is able to improve regional perfusion in septic shock patients studied by muscle microdialysis

NCT ID: NCT02961166 Completed - Septic Shock Clinical Trials

Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients

IVIG
Start date: January 2012
Phase:
Study type: Observational

57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy. These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.

NCT ID: NCT02934997 Completed - Sepsis Clinical Trials

The Role of Dysfunctional HDL in Sepsis

Start date: November 1, 2016
Phase:
Study type: Observational

To determine the role of dysfunctional high density lipoprotein (Dys-HDL) in predicting or mediating progression to chronic critical illness or morbid long-term outcomes in patients being treated for community-acquired or hospital-acquired sepsis.

NCT ID: NCT02918214 Completed - Septic Shock Clinical Trials

Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock

PRODIASYS2
Start date: January 2017
Phase:
Study type: Observational

Sepsis induces a reversible systolic and diastolic cardiac dysfunction. The presence of a left ventricular (LV) diastolic dysfunction during septic shock could favor harmful volume overload. Recently, a meta-analysis suggested a negative prognostic role of LV diastolic dysfunction in septic patients (Od Ratio: 1.82; 95%CI: 1.12 - 2.97; p = 0.02) but its external validity is hampered by the numerous limits and the heterogeneity of the studies. To date, a pathophysiological link between LV diastolic dysfunction associated with septic shock and the water balance (reflecting volume overload) remains to establish. In addition, small size studies reported an excess of mortality in patients with septic shock who were diagnosed with a high cardiac output. However, no large cohort has yet confirmed the negative prognostic role of a hyperkinetic hemodynamic profile at the initial phase of septic shock.

NCT ID: NCT02899143 Recruiting - Sepsis Clinical Trials

Short-course Antimicrobial Therapy in Sepsis

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effect of a short course antimicrobial therapy (5-days) versus a 10-days therapy on sepsis-related organ dysfunction.

NCT ID: NCT02887274 Recruiting - Sepsis Clinical Trials

Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis

SIRCSS
Start date: July 2013
Phase:
Study type: Observational

Persistence of a marked compensatory anti-inflammatory innate immune response after an insult is termed immunoparalysis. There is no biomarker available to determine the immune status of patient. Thus, the need for early and definite diagnosis of immune status of patient with sepsis, as well as the identification of patients at risk of evolving with severe organ dysfunctions, is crucial. Most important of all, speed is the key to survival. Therefore, it of crucial importance to identify which patient characteristic determines the poor prognosis. Early intervention can improve the prognosis. Investigators foresee an urgent need to identify predictors for mortality in severe sepsis, including clinical factors or immune status. Recently, the PIRO model has been proposed as a way of stratifying septic patients according to their Predisposing condition, the severity of Infection, the Response to therapy and the degree of Organ dysfunction. The immune status may be associated with above model. However, there is paucity data addressing this issue. In this study, investigators will also analyze the progression of patient condition during treatment and the associated immune status change. In the future, Investigators hope the determination of immune status may contribute to this model of classification rather than just being used as prognostic markers. Despite the advances in the knowledge of the basic processes that trigger and sustain the systemic inflammatory response in sepsis, the search for a "magic bullet" to treat this syndrome has been frustrating. The incidence of severe sepsis and septic shock still remains quite high, as does its mortality, which has decreased very little over the past decades.

NCT ID: NCT02885688 Withdrawn - Septic Shock Clinical Trials

Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if adding liquid nutrition therapy that is given by vein to standard-of-care treatment for sepsis can help to control sepsis symptoms better than giving standard-of-care treatment alone. Researchers also want to compare the length of ICU and hospital stay and any side effects between these 2 treatments.

NCT ID: NCT02885168 Completed - Septic Shock Clinical Trials

Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C

PCA
Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated with dose-response curve is diminished in septic shock and ameliorated by activated protein C (APC). This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen species (ROS) markers and increase of circulating catecholamines.